Takeda has concluded the previously announced acquisition of the complete shares of Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) programme subsidiary Nimbus Lakshmi.
The latest move comes following clearance from the United States Federal Trade Commission and after satisfaction of other conditions related to the deal closure.
Takeda originally signed the acquisition agreement in December last year.
According to the agreement and following the deal completion, Nimbus will receive nearly $4bn in upfront payment from Takeda.
This payment will be made after adjusting items including closing account payable and closing indebtedness of Lakshmi.
Additionally, Nimbus is eligible for two milestone payments of $1bn each from Takeda after achieving $4bn in annual net sales and $5bn of products developed from the TAK-279 programme.
Takeda global portfolio division president Ramona Sequeira said: “With our plan to acquire announced in December, we are excited to have promptly added TAK-279, a highly selective oral TYK2 inhibitor with truly transformative potential for patients in multiple diseases, to our late-stage pipeline.
“This programme closely aligns with our strategy and expertise in immune-mediated diseases, and we look forward to sharing more details of our development plans soon.”
With this transaction, Takeda has now acquired TAK-279, formerly known as NDI-034858 at Nimbus.
Phase III clinical trial of TAK-279 in psoriasis is expected to commence this year.
TAK-279 is said to have the potential to demonstrate safety, efficacy and convenience in psoriasis and other immune-mediated diseases.
These diseases include psoriatic arthritis, inflammatory bowel disease and systemic lupus erythematosus.
Takeda noted that the acquisition would boost its growing late-stage pipeline while expanding its portfolio.
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.